BE2014C027I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C027I2
BE2014C027I2 BE2014C027C BE2014C027C BE2014C027I2 BE 2014C027 I2 BE2014C027 I2 BE 2014C027I2 BE 2014C027 C BE2014C027 C BE 2014C027C BE 2014C027 C BE2014C027 C BE 2014C027C BE 2014C027 I2 BE2014C027 I2 BE 2014C027I2
Authority
BE
Belgium
Application number
BE2014C027C
Other languages
Dutch (nl)
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BE2014C027I2 publication Critical patent/BE2014C027I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C027C 2003-08-01 2014-04-29 BE2014C027I2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49153403P 2003-08-01 2003-08-01
PCT/JP2004/011312 WO2005012326A1 (en) 2003-08-01 2004-07-30 Novel compounds having inhibitory activity against sodium-dependant transporter

Publications (1)

Publication Number Publication Date
BE2014C027I2 true BE2014C027I2 (uk) 2023-12-14

Family

ID=34115515

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C027C BE2014C027I2 (uk) 2003-08-01 2014-04-29

Country Status (37)

Country Link
US (3) US7943788B2 (uk)
EP (4) EP3251679B1 (uk)
JP (2) JP4130466B2 (uk)
KR (2) KR100778988B1 (uk)
CN (4) CN103214471B (uk)
AR (1) AR045173A1 (uk)
AU (1) AU2004260761B2 (uk)
BE (1) BE2014C027I2 (uk)
BR (1) BRPI0413232B8 (uk)
CA (1) CA2534024C (uk)
CR (2) CR8188A (uk)
CY (3) CY1113813T1 (uk)
DK (2) DK2896397T4 (uk)
EA (2) EA010299B1 (uk)
ES (4) ES2844401T3 (uk)
FR (1) FR14C0034I2 (uk)
HK (1) HK1086277A1 (uk)
HR (2) HRP20130124T4 (uk)
HU (2) HUE037320T2 (uk)
IL (2) IL173050A (uk)
LT (1) LT2896397T (uk)
LU (1) LU92426I2 (uk)
ME (1) ME00411B (uk)
MX (1) MXPA06001274A (uk)
MY (1) MY143203A (uk)
NL (1) NL300670I2 (uk)
NO (3) NO333933B1 (uk)
NZ (2) NZ545304A (uk)
PL (2) PL1651658T5 (uk)
PT (2) PT1651658E (uk)
RS (1) RS53365B (uk)
SG (1) SG145694A1 (uk)
SI (2) SI1651658T2 (uk)
TW (2) TWI365190B (uk)
UA (1) UA83243C2 (uk)
WO (1) WO2005012326A1 (uk)
ZA (5) ZA200601685B (uk)

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
EP1980560B1 (en) 2003-03-14 2011-05-25 Astellas Pharma Inc. C-glycoside derivatives for the treatment of diabetes
BRPI0413232B8 (pt) † 2003-08-01 2021-05-25 Mitsubishi Tanabe Pharma Corp composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
CN1934103B (zh) * 2004-03-04 2011-06-01 橘生药品工业株式会社 稠杂环衍生物，包含稠杂环衍生物的药物组合物及其医药用途
CA2557801C (en) 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
JP2008508213A (ja) * 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
EP1803729A4 (en) * 2004-09-29 2008-10-01 Kissei Pharmaceutical HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND
WO2006064033A2 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP4496174B2 (ja) * 2005-01-31 2010-07-07 田辺三菱製薬株式会社 医薬組成物
MY147375A (en) * 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
ES2334940T3 (es) 2005-02-23 2010-03-17 Boehringer Ingelheim International Gmbh Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2).
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
ATE468347T1 (de) 2005-07-27 2010-06-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)- benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters (sglt)
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US8507450B2 (en) 2005-09-08 2013-08-13 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
EP1989191B1 (en) 2006-02-15 2011-07-20 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5230613B2 (ja) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2664095A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008044762A1 (fr) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
NZ577391A (en) * 2006-12-04 2011-11-25 Janssen Pharmaceutica Nv Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101568537A (zh) 2006-12-21 2009-10-28 安斯泰来制药有限公司 C-糖苷衍生物的制造方法及其合成中间体
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
WO2008103618A1 (en) * 2007-02-22 2008-08-28 University Of Utah Research Foundation Synthesis of novel xylosides and potential uses thereof
RU2492175C2 (ru) * 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
CA2684021A1 (en) * 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of an enantiomer of a tetracyclic benzazepine
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
JP5596545B2 (ja) * 2007-09-10 2014-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2236137B1 (en) 2008-01-31 2015-06-24 Astellas Pharma Inc. Pharmaceutical composition for treatment of fatty liver diseases
CL2009000309A1 (es) * 2008-02-13 2009-06-26 Sanofi Aventis Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
ME02702B (me) 2008-08-22 2017-10-20 Theracos Sub Llc Postupci za pripremu inhibitora sgl t2
RS52236B (en) 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
CA2737831A1 (en) * 2008-09-19 2010-03-25 Novartis Ag Glucoside derivatives and uses thereof as sglt inhibitors
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
CN101830876A (zh) * 2009-03-12 2010-09-15 上海恒瑞医药有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
US8147801B2 (en) * 2009-09-15 2012-04-03 Janssen Pharmaceutica, N.V. Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion
KR101813025B1 (ko) 2009-09-30 2017-12-28 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실­치환된 벤질­벤젠 유도체의 제조방법
MX2012002942A (es) 2009-09-30 2012-04-11 Boehringer Ingelheim Int Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US9174971B2 (en) 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
CN102115468B (zh) * 2009-12-31 2014-06-11 上海特化医药科技有限公司 一种2,5-二取代噻吩化合物的合成方法
CN102134226B (zh) 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
AU2011237775A1 (en) 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2011142478A1 (en) 2010-05-11 2011-11-17 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
US8217183B2 (en) 2010-05-18 2012-07-10 Corning Incorporated Methods of making fused thiophenes
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
TWI541030B (zh) * 2010-07-06 2016-07-11 健生藥品公司 用於糖尿病協同治療之調配物
CN102372722A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012033390A2 (en) * 2010-09-10 2012-03-15 Green Cross Corporation Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
CN103539791B (zh) 2010-09-22 2017-01-11 艾尼纳制药公司 Gpr119 受体调节剂和对与其相关的障碍的治疗
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012109996A1 (zh) 2011-02-18 2012-08-23 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
AU2012241897C1 (en) * 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
EP2697203B1 (en) * 2011-04-13 2017-05-24 Merck Sharp & Dohme Corporation Mineralocorticoid receptor antagonists
EP2697240B1 (en) * 2011-04-14 2015-09-16 Novartis AG Glycoside derivatives and uses thereof
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9522931B2 (en) 2011-05-20 2016-12-20 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT-2
JP2014516038A (ja) * 2011-05-20 2014-07-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ−２の阻害物質として有用な化合物の調製プロセス
WO2012165914A2 (en) * 2011-06-01 2012-12-06 Green Cross Corporation Novel diphenylmethane derivatives as sglt2 inhibitors
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102827122B (zh) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 糖苷衍生物
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013061105A2 (en) * 2011-10-28 2013-05-02 Debreceni Egyetem Glycogen phosphorylase inhibitors
TW201335176A (zh) * 2011-12-15 2013-09-01 Nat Health Research Institutes 新穎醣苷化合物
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN103570671B (zh) * 2012-09-26 2016-03-30 上海天慈生物谷生物工程有限公司 一种降糖化合物及其制法和应用
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014094544A1 (zh) * 2012-12-17 2014-06-26 天津药物研究院 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2963048B1 (en) * 2013-02-26 2020-11-18 Mitsubishi Tanabe Pharma Corporation Method for producing alpha-halo-tetraacyl glucose
EP2968258B1 (en) * 2013-03-11 2020-02-12 Janssen Pharmaceutica NV Dual sglt1/sglt2 inhibitors
EP2968375B1 (en) 2013-03-14 2019-06-12 MSD International GmbH Methods for preparing sglt2 inhibitors
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
DK2981269T3 (da) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh Behandling af stofskifteforstyrrelser hos hestedyr
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (es) 2013-04-18 2022-04-13 Boehringer Ingelheim Int Composición farmacéutica, métodos de tratamiento y usos de la misma
US10323056B2 (en) 2013-05-08 2019-06-18 Lek Pharmaceuticals D.D. Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
WO2014195966A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited Amorphous form of canagliflozin and process for preparing thereof
CN104418834B (zh) * 2013-08-23 2017-09-15 重庆博腾制药科技股份有限公司 一种抗糖尿病药物中间体的合成方法
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN104557894A (zh) * 2013-10-18 2015-04-29 上海信谊药厂有限公司 坎格列汀晶型及其制备方法
KR20240017116A (ko) 2013-12-17 2024-02-06 베링거잉겔하임베트메디카게엠베하 고양이과 동물에서 대사 장애의 치료
ES2951127T3 (es) 2014-01-23 2023-10-18 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
CA2938406A1 (en) 2014-01-31 2015-08-06 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
EP2918579A1 (en) 2014-03-14 2015-09-16 LEK Pharmaceuticals d.d. Synthesis of 2-arylmethyl-5-aryl-thiophene
US10174010B2 (en) 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CN103936725B (zh) * 2014-04-01 2016-07-27 天津大学 卡格列净的c晶型及其结晶制备方法
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
EP2933255A1 (en) 2014-04-17 2015-10-21 LEK Pharmaceuticals d.d. Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN103980263B (zh) * 2014-04-17 2016-08-03 海门瑞一医药科技有限公司 卡格列净的合成工艺
CN103936800A (zh) * 2014-05-08 2014-07-23 安徽联创药物化学有限公司 1-(1-甲氧基吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的制备方法
TW201623321A (zh) * 2014-05-13 2016-07-01 韓美藥品股份有限公司 雙環衍生物及包含其之藥學組成物
EP2947077A1 (en) 2014-05-19 2015-11-25 LEK Pharmaceuticals d.d. Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides
WO2015181692A1 (en) * 2014-05-27 2015-12-03 Glenmark Pharmaceuticals Limited Process for preparation of canagliflozin
CN105319294B (zh) * 2014-06-20 2021-03-30 重庆医药工业研究院有限责任公司 一种分离测定卡格列净及其有关物质的方法
US20160002275A1 (en) * 2014-07-03 2016-01-07 Cadila Healthcare Limited Process for preparation and purification of canagliflozin
CN104119324B (zh) * 2014-07-23 2016-03-30 齐鲁天和惠世制药有限公司 一种卡格列净的制备方法
CN104109157B (zh) * 2014-08-04 2016-05-25 山东康美乐医药科技有限公司 卡格列净的制备方法
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
WO2016035042A1 (en) 2014-09-05 2016-03-10 Mylan Laboratories Ltd Process for the preparation of canagliflozin
CN104292209A (zh) * 2014-09-11 2015-01-21 浙江丽晶化学有限公司 一种制备2-(4-氟苯基)噻吩(化合物v)的新方法
CZ2014634A3 (cs) 2014-09-16 2016-03-23 Zentiva, K.S. Komplexy canagliflozinu a cyklodextrinů
CN104817554A (zh) * 2014-11-10 2015-08-05 镇江新元素医药科技有限公司 一类葡萄糖苷衍生物及其药物组合物
CN104447905A (zh) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104478969A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含烷氧苯基噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104447906A (zh) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 烷氧苯基双葡萄糖苷衍生物、其制备方法和用途
CN104447907A (zh) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 含硝基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478962A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一类卤代苯基s-葡萄糖苷衍生物、其制备方法和用途
EP3256482B1 (en) 2015-02-09 2019-11-27 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
CN105884755B (zh) * 2015-02-14 2019-05-28 正大天晴药业集团股份有限公司 氘修饰的碳甙衍生物
EP3260451A4 (en) * 2015-02-19 2018-07-18 JNC Corporation Liquid crystalline compound having benzothiophene, liquid crystal composition and liquid crystal display element
EP3262039A4 (en) * 2015-02-27 2018-11-14 MSN Laboratories Private Limited Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
CN104803977A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 一种含四氮唑结构的ptp1b衍生物、其制备方法及用途
WO2016142950A1 (en) * 2015-03-11 2016-09-15 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
ES2817526T3 (es) 2015-05-22 2021-04-07 Janssen Pharmaceutica Nv Forma cristalina anhidra de (1S)-1,5-anhidro-1-[3-[[5-(4-fluorofenil)-2-tienil]metil]-4-metilfenil]-D-glucitol
CN104926803B (zh) * 2015-06-17 2017-12-22 南通常佑药业科技有限公司 一种新的sglt2抑制剂药物的制备方法
CZ2015435A3 (cs) 2015-06-25 2017-01-04 Zentiva, K.S. Pevné formy amorfního canagliflozinu
CN104987320A (zh) * 2015-08-03 2015-10-21 沧州那瑞化学科技有限公司 一种坎格列净中间体的制备方法
US10428053B2 (en) 2015-09-15 2019-10-01 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2017046655A1 (en) * 2015-09-16 2017-03-23 Optimus Drugs (P) Ltd A novel process for the preparation of canagliflozin
US10370365B2 (en) 2015-09-16 2019-08-06 Optimus Drugs (P) Limited Process for the preparation of Canagliflozin
CZ2015729A3 (cs) 2015-10-13 2017-04-26 Zentiva, K.S. Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
CN105503845A (zh) * 2015-12-01 2016-04-20 北京普德康利医药科技发展有限公司 去氟卡格列净化合物及其制备方法和应用
WO2017093949A1 (en) * 2015-12-04 2017-06-08 Dr. Reddy's Laboratories Limited Substantially pure canagliflozin
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
PT3394051T (pt) 2015-12-21 2020-06-08 Janssen Pharmaceutica Nv Procedimento de cristalização para obtenção de cristais de canagliflozina hemi-hidratada
CN105541815B (zh) * 2015-12-24 2018-07-13 寿光富康制药有限公司 一种卡格列净的制备方法
WO2017141202A1 (en) 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
ES2898336T3 (es) * 2016-06-17 2022-03-07 Dae Woong Pharma Derivado de difenilmetano en forma cristalina
WO2018020506A1 (en) 2016-07-25 2018-02-01 Natco Pharma Ltd Process for the preparation of amorphous form of canagliflozin
AU2017344882A1 (en) 2016-10-19 2019-03-28 Boehringer Ingelheim International Gmbh Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
CN106588898A (zh) 2017-02-20 2017-04-26 浙江华海药业股份有限公司 一种卡格列净无定型的制备方法
CN110869380A (zh) 2017-05-09 2020-03-06 皮拉马尔企业有限公司 用于制备sglt2抑制剂和其中间体的方法
AU2018283781B2 (en) 2017-06-12 2023-09-28 Janssen Pharmaceutica Nv Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus
CN108017612B (zh) * 2017-11-29 2020-06-09 南通常佑药业科技有限公司 一种坎格列净中间体的制备方法
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
TW202024046A (zh) * 2018-09-06 2020-07-01 日商德山股份有限公司 β－Ｃ－芳基糖苷衍生物的製造方法
CA3118629A1 (en) 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
TW202103709A (zh) 2019-03-26 2021-02-01 比利時商健生藥品公司 用於治療患有慢性腎臟病之對象的方法
US11759474B2 (en) 2019-11-28 2023-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
CN110981851A (zh) * 2019-12-24 2020-04-10 艾希尔（深圳）药物研发有限公司 一种卡格列净杂质的制备方法
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
CN115916197A (zh) 2020-04-22 2023-04-04 拜耳公司 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
CN113429379A (zh) * 2021-06-28 2021-09-24 江苏法安德医药科技有限公司 一种lh-1801中间体及其制备方法和应用
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物，特别是犬科动物中预防和/或治疗心脏疾病的用途
KR20240040106A (ko) 2021-07-28 2024-03-27 베링거잉겔하임베트메디카게엠베하 비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1476537A (fr) * 1965-05-10 1967-04-14 Chimetron Sarl Glucosides dérivés du benzimidazole
US4160861A (en) 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4584369A (en) 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
JP2544609B2 (ja) 1986-10-07 1996-10-16 和光純薬工業株式会社 Ｔｃｎｑ錯体
CA1334969C (en) 1988-08-19 1995-03-28 Mark James Suto Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
HU203896B (en) 1988-10-26 1991-10-28 Biogal Gyogyszergyar Process for producing glycosides of aromatic amines
JPH04253974A (ja) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
US5149838A (en) 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en) 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US6297363B1 (en) 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1997025033A1 (en) 1995-10-31 1997-07-17 Eli Lilly And Company Antithrombotic diamines
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JPH09263549A (ja) 1996-01-25 1997-10-07 Fujisawa Pharmaceut Co Ltd ベンゼン誘導体の製造法
DK0850948T3 (da) 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JPH10324632A (ja) 1997-03-25 1998-12-08 Takeda Chem Ind Ltd 医薬組成物
JP2000034239A (ja) 1998-07-16 2000-02-02 Asahi Glass Co Ltd トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja) 1998-07-17 2006-12-13 ポーラ化成工業株式会社 含硫黄抗真菌剤
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
CA2401697A1 (en) 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
KR100660738B1 (ko) * 2000-03-17 2006-12-22 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ATE455785T1 (de) 2000-11-02 2010-02-15 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
US6476352B2 (en) 2000-12-18 2002-11-05 General Electric Company Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
HU228915B1 (en) 2000-12-28 2013-06-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof
DE60230591D1 (de) 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
JP4147111B2 (ja) 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
EP2295475A1 (en) 2001-03-02 2011-03-16 University of Western Ontario Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
JP4292570B2 (ja) 2001-04-27 2009-07-08 味の素株式会社 Ｎ−置換ピラゾール−ｏ−グリコシド誘導体及びそれらを含有する糖尿病治療薬
GB0112122D0 (en) 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
WO2003000712A1 (fr) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
WO2003035896A2 (en) 2001-10-24 2003-05-01 Michael Burton Chromogenic enzyme substrates and method for detecting beta-d-ribofuranosidase activity
DK1443915T3 (da) 2001-11-16 2006-10-23 Cutanix Corp Farmaceutiske og kosmetiske præparater indeholdende aromatiske aldehyder, der bærer en oxygruppe
US6617313B1 (en) 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
ES2326638T3 (es) 2002-04-18 2009-10-16 Astrazeneca Ab Compuestos heterociclicos.
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
CA2478889A1 (en) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004019958A1 (ja) 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2512389A1 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Methods of producing c-aryl glucoside sglt2 inhibitors
EP1980560B1 (en) * 2003-03-14 2011-05-25 Astellas Pharma Inc. C-glycoside derivatives for the treatment of diabetes
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
EP1637539B1 (en) 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
BRPI0413232B8 (pt) † 2003-08-01 2021-05-25 Mitsubishi Tanabe Pharma Corp composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
AU2004261664A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-O-glucosides
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
CA2549022A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
CA2549017A1 (en) 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides

Also Published As

Publication number Publication date
JP2008266328A (ja) 2008-11-06
IL173050A (en) 2011-06-30
RS53365B (sr) 2014-10-31
US20110105424A1 (en) 2011-05-05
EA200800924A1 (ru) 2008-08-29
IL173050A0 (en) 2006-06-11
CN103214471B (zh) 2018-02-06
HRP20130124T1 (hr) 2013-04-30
ZA200603882B (en) 2010-03-31
NO334706B1 (no) 2014-05-12
WO2005012326A1 (en) 2005-02-10
TWI365190B (en) 2012-06-01
US7943788B2 (en) 2011-05-17
SI2896397T2 (sl) 2020-12-31
RS20060079A (en) 2008-04-04
ES2649737T3 (es) 2018-01-15
JP5065135B2 (ja) 2012-10-31
FR14C0034I2 (fr) 2014-11-14
PL2896397T3 (pl) 2018-03-30
PL2896397T5 (pl) 2023-06-19
EP2896397B2 (en) 2020-10-07
ZA200603881B (en) 2010-01-27
CN104109155A (zh) 2014-10-22
US20120058941A1 (en) 2012-03-08
TWI385177B (zh) 2013-02-11
UA83243C2 (uk) 2008-06-25
HRP20171838T1 (hr) 2018-01-12
CA2534024A1 (en) 2005-02-10
EP2514756B1 (en) 2014-12-17
ES2531660T3 (es) 2015-03-18
BRPI0413232A (pt) 2006-10-03
EP1651658B1 (en) 2013-01-16
PT2896397T (pt) 2017-11-23
ME00411B (me) 2011-10-10
CN103214471A (zh) 2013-07-24
CY2014016I1 (el) 2015-12-09
CN1829729A (zh) 2006-09-06
HRP20171838T4 (hr) 2021-02-05
AU2004260761B2 (en) 2008-01-31
HUE037320T2 (hu) 2018-08-28
LU92426I9 (uk) 2019-01-16
CY1113813T1 (el) 2015-12-09
BRPI0413232B1 (pt) 2018-03-06
NZ545304A (en) 2009-04-30
AR045173A1 (es) 2005-10-19
PT1651658E (pt) 2013-03-07
CY1119814T1 (el) 2018-06-27
ES2649737T5 (es) 2021-07-07
CR8188A (es) 2006-07-14
IL206831A (en) 2012-06-28
SI1651658T2 (sl) 2020-12-31
NO20120585L (no) 2006-05-02
CR11263A (es) 2010-05-19
NZ575711A (en) 2010-05-28
US8222219B2 (en) 2012-07-17
JP4130466B2 (ja) 2008-08-06
DK1651658T3 (da) 2013-02-18
EA015104B1 (ru) 2011-06-30
HRP20130124T4 (hr) 2020-11-13
NO2014009I2 (no) 2016-08-01
US20050233988A1 (en) 2005-10-20
KR100778988B1 (ko) 2007-11-28
CN103819465A (zh) 2014-05-28
DK2896397T3 (da) 2017-11-06
NO2014009I1 (no) 2014-06-02
JP2007518683A (ja) 2007-07-12
MXPA06001274A (es) 2006-04-11
NO20060220L (no) 2006-05-02
US8202984B2 (en) 2012-06-19
NL300670I2 (uk) 2016-09-22
KR100942622B1 (ko) 2010-02-17
EP2896397A1 (en) 2015-07-22
EP2514756A1 (en) 2012-10-24
CY2014016I2 (el) 2015-12-09
AU2004260761A1 (en) 2005-02-10
EP3251679B1 (en) 2020-12-16
PL1651658T3 (pl) 2013-05-31
DK2896397T4 (da) 2020-11-16
TW201038588A (en) 2010-11-01
LT2896397T (lt) 2017-11-27
NO333933B1 (no) 2013-10-28
MEP61208A (en) 2011-05-10
EP1651658B2 (en) 2020-08-12
ZA200700550B (en) 2009-08-26
SG145694A1 (en) 2008-09-29
TW200510441A (en) 2005-03-16
EP2896397B1 (en) 2017-09-06
EP3251679A1 (en) 2017-12-06
FR14C0034I1 (uk) 2014-06-13
IL206831A0 (en) 2011-08-01
ES2402098T3 (es) 2013-04-26
EA010299B1 (ru) 2008-08-29
LU92426I2 (fr) 2014-06-10
KR20060057589A (ko) 2006-05-26
SI1651658T1 (sl) 2013-04-30
DK1651658T4 (da) 2020-11-09
ZA200601685B (en) 2007-05-30
CA2534024C (en) 2009-06-02
KR20070065454A (ko) 2007-06-22
BRPI0413232B8 (pt) 2021-05-25
PL1651658T5 (pl) 2020-11-30
SI2896397T1 (en) 2018-01-31
EA200600351A1 (ru) 2006-08-25
ES2844401T3 (es) 2021-07-22
MY143203A (en) 2011-03-31
HK1086277A1 (en) 2006-09-15
ES2402098T5 (es) 2021-06-09
EP1651658A1 (en) 2006-05-03
HUS1400021I1 (hu) 2016-08-29
ZA200603879B (en) 2010-01-27

Similar Documents

Publication Publication Date Title
NL300670I2 (uk)
BE2013C075I2 (uk)
BE2013C070I2 (uk)
BE2013C067I2 (uk)
BE2013C038I2 (uk)
BE2013C036I2 (uk)
BE2011C030I2 (uk)
JP2003320808A5 (uk)
BE2012C053I2 (uk)
JP2004216063A5 (uk)
BE2015C024I2 (uk)
AU2002329412A1 (uk)
AU2003207750A1 (uk)
AU2002362930A1 (uk)
AU2002239060A1 (uk)
AU2003207787A1 (uk)
AU2002245368A1 (uk)
AU2003210772A1 (uk)
AU2002324323A1 (uk)
AU2002327736A1 (uk)
ECSDI034473S (uk)
AU2002322913A1 (uk)
AU2001256599A1 (uk)
AU2002351829A1 (uk)
AU2002318342A1 (uk)